Organogenesis Faces Setback as Knee Osteoarthritis Therapy Fails Trial Endpoint

Organogenesis has encountered a significant setback as its knee osteoarthritis therapy failed to meet the primary endpoint in a recent clinical trial, leading to a drop in its stock price. This outcome raises concerns about the treatment's effectiveness and could adversely affect investor confidence and the company's future strategies in developing osteoarthritis therapies.